Objectives: This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy.

Methods: A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress.

Results: Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression.

Conclusion: Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect..

目的：这是一个叙述性综述，调查了用于治疗糖尿病的药物的抗氧化特性，并讨论了这些抗氧化作用是否有助于，混淆或掩盖抗氧化疗法的作用。

方法：使用Web of Science，PubMed和Ovid，系统地搜索了报道试验的文章或关于用于治疗人或动物的糖尿病的药物的抗氧化作用的观察性研究。提取数据，包括许多受试者的数据，所接受的治疗类型（和疗程）以及主要和次要结果。主要结果是报告抗氧化剂浓度的生物标志物的变化，次要结果是报告氧化应激的生物标志物的变化。

结果：糖尿病是一种以氧化应激增加为特征的疾病。它经常伴有一系列其他代谢紊乱，包括血浆脂质升高，尿酸升高，高血压，内皮功能障碍和中枢性肥胖。这篇综述显示了一些糖尿病管理药物通过清除自由基和上调抗氧化剂基因表达等机制具有体内和体外抗氧化特性。

结论：已证明用于治疗2型糖尿病的药物具有抗氧化作用。